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Platelets play a very important role in the pathogenesis of acute vascular events leading to thrombosis of the coronary and cerebral
arteries.Blockageofthesearteriesleadingtoregionalischemiaofheartandbraintissuesprecipitateheartattacksandstroke.Acetyl
salicylicacid (Aspirin)hasbeenthedrugofchoiceforoverhalfacenturyfortheprimaryandsecondaryprophylaxisofthrombotic
events. In spite of its extensive use as an antiplatelet drug for the prevention of vascular thrombosis, there is considerable concern
about the degree of protection it oﬀers, to patients under aspirin therapy. In this paper, we explain the phenomenon of aspirin
resistance, discuss the limitations of aspirin therapy, and suggest methods to monitor “at-risk” individuals. Ability to monitor and
determine at risk patients will provide opportunities for the clinicians to customize antiplatelet therapies.
1.Introduction
Roleofplateletsinthepathogenesisofthrombosisandstroke
is well documented [1]. There is a great need for developing
speciﬁc and eﬀective antiplatelet drugs for modulating
platelet function. A thorough understanding of the signaling
mechanisms involved in the regulation of platelet function
will facilitate the development of better antiplatelet drugs.
Agonists interact with the platelet at speciﬁc receptor sites on
the plasma membrane and initiate a series of signaling events
capable of modulating shape change, adhesion, aggregation,
secretion of granule contents, and expression of activation
markers on the membrane [2, 3]. Platelet aggregates are
formed when the GP11b/111a receptors get activated and
bind ﬁbrinogen and recruit other platelets to form clumps of
activated cells. This phenomenon of platelet activation plays
a signiﬁcant role in the formation of eﬀective haemostatic
plug as well as the growth of thrombus. Weak agonists such
as epinephrine, ADP require the production of proaggre-
gatory prostaglandin (PG) endoperoxides and thromboxane
to cause platelet aggregation and secretion. Aspirin is a
speciﬁc inhibitor of cyclooxygenase (COX-1) and prevents
the formation of pro-aggregatory PG endoperoxides.
Data from large number of clinical studies have demon-
strated that at any given risk for the development of acute
vascular events, irrespective of the disease state, aspirin at
low-to-medium concentration is as eﬀective as any other
drug in reducing the risks [4]. Although ability of aspirin
to reduce fever was discovered two hundred years ago, the
mechanism of action of aspirin remained elusive till late
1900 [5]. Nobel laureate Sir John R. Vane and his associates
in 1971 proposed the mechanism as to how aspirin works
[6, 7]. Within a short period of time extensive work was
done by various groups to elucidate the mechanism of
action of aspirinlike compounds [8–20]. At the same period,
another Nobel Laureate Dr. Bengt Samuelsson discovered
that the prostaglandin synthase produces transient bioactive
prostanoids like PGG2/PGH2 and thromboxane A2 from the
substrate arachidonic acid [9]. These ﬁndings revolutionized
theresearchinplateletphysiologyandpharmacology[2–21].2 Thrombosis
2.PlateletPhysiology
Blood platelets interact with a variety of soluble agonists
such as epinephrine (EPI), adenosine diphosphate (ADP),
thrombin, and thromboxane (TXA2) and many cell matrix
components, including collagen, laminin, ﬁbronectin, and
von Willebrand factor and biomaterials used for construc-
tion of invasive medical devices [21–26]. These interactions
stimulate speciﬁc receptors and glycoprotein-rich domains
(integrin and nonintegrin receptors) on the plasma mem-
brane and lead to the activation of intracellular eﬀector
enzymes. Agonist–mediated activation of platelets stimulates
phospholipase C (PLC) and induces the hydrolysis of
Phosphatidyl inositol 4, 5-bisphosphate and formation of
second messengers 1, 2-diacyl glycerol and inositol 1, 4,
5 trisphosphate. Diacylglycerol activates protein kinase and
inositol trisphosphate facilitates the mobilization of free
calcium from the storage sites. The majority of regulatory
events appear to require free calcium. Ionized calcium is the
primary bioregulator, and a variety of biochemical mech-
anisms modulate the availability of free calcium [26]. El-
evation of cytosolic calcium stimulates phospholipase A2
and liberates arachidonic acid (AA) from platelet mem-
brane phospholipids. Free AA is transformed to a novel
metabolite thromboxane, a potent platelet agonist. This
is the major metabolite of AA metabolism that plays an
important role in platelet recruitment, granule mobilization,
secretion of granule contents, and expression of activated
GP11b/111a (´ α11b β3)r e c e p t o r s[ 21–28]. Upregulation of
activationsignalingpathwayswillincreasetheriskforclinical
complications associated with thrombotic events.
3.ArachidonicAcidMetabolism
Arachidonic acid is a 20-carbon polyunsaturated fatty
acid (20:4w6), found in platelet membrane phospholipids.
Platelet activation stimulates Phospholipase A2, which facili-
tates the release of this fatty acid from membrane phospho-
lipids. AA is converted to prostaglandin (PG) endoperoxides
(PGG2/PGH2) by cyclooxygenase (Prostaglandin G/H syn-
thase; COX1). These metabolites are converted by throm-
boxane synthetase to thromboxane A2, which is the major
metabolite of this pathway in platelets [9]. Whereas, in
vascular tissues, the endoperoxides generated by COX1
are transformed by prostacyclin synthetase to prostacyclin
(PGI2). Thromboxane is a potent platelet agonist and a
vasoconstrictor. Prostacyclin is an antiplatelet compound
and exerts vasodilatory eﬀects on vascular tissues. Thus
from a single substrate (AA), two pharmacologically oppos-
ing vasoactive prostanoids are generated by platelets and
vascular tissues [2, 3]. Aspirin selectively acetylates the
hydroxyl groups of a single serine residue (position 529)
in the prostaglandin G/H synthase and causes irreversible
inhibition of the activity of this enzyme [11, 12]. Inhibition
of PG synthase results in the decreased conversion of AA
to PG endoperoxides, PGG2/PGH2. Molecular mechanisms
involved in aspirin-mediated inhibition of prostaglandin
G/H synthase are well documented [3, 14].
4.Studieson the Use of Aspirinas an
Inhibitor of CyclooxygenaseEnzymes
Single oral doses of 10–100mgs of aspirin can signiﬁcantly
inhibit the platelet PG synthase activity [29]. The inhibitory
eﬀect of aspirin on circulating platelets in the blood is for a
very limited time and probably occurs in the portal circula-
tion. The half-life of aspirin is very short (15–20minutes),
but suﬃcient to inhibit PG synthase of circulating platelets.
Since these cells lack DNA and the ability to resynthesize
the enzyme, the dysfunction caused by aspirin cannot be
overcome. Therefore, platelets exposed to aspirin loose the
ability to make the prostanoids completely. However, one
should keep in mind that once the aspirin is hydrolyzed
to salicylic acid, ability to inhibit prostaglandin synthase is
lost. Hence the platelets produced from the marrow after the
aspirin is hydrolyzed will have active prostaglandin synthase.
Approximately 10% of fresh platelets are added on to the
circulating blood every day. Although aspirin-treated blood
platelets do not make prostaglandins, they respond with
aggregation to the stimulation by prostaglandin endoper-
oxides and thromboxane. Fresh platelets formed after the
hydrolysis of aspirin can synthesize prostanoids and these
newly formed metabolites of AA can cause aggregation of
aspirin exposed platelets. In view of the fact that aspirin
irreversibly inhibits prostaglandin synthase, it is possible
to take advantage of repeated low-dose aspirin to achieve
a cumulative eﬀect [29–42]. Even doses as low as 30–
50mg aspirin taken daily will suppress platelet thromboxane
synthesis signiﬁcantly in 5 to 10 days. Vascular tissues on
the other hand have the ability to resynthesize prostaglandin
G/H synthase [29]. Therefore, these cells can recover the
enzyme activity following aspirin exposure. It is, therefore,
possible to develop a strategy to promote the biochemical
selectivity of aspirin in terms of inhibition of platelet
prostaglandin synthase. This is done by modiﬁcation of the
drug delivery, so the amount of drug delivered is just enough
to inhibit platelet enzymes in the peripheral circulation
and spare the systemic eﬀect on vascular endothelium [30,
31]. Several studies have demonstrated the feasibility of
this approach and various control release or timed release
formulationshavebeendevelopedforthisnoveltherapy[30–
32].
As mentioned earlier, aspirin is metabolized rapidly and
the major metabolite, salicylic acid, is a poor inhibitor of
platelet prostaglandin synthase. Therefore, it is essential to
develop appropriate strategies to maximize the beneﬁcial
eﬀect of this novel drug. As low-dose as 20mg taken daily
reduces the platelet thromboxane formation by more than
90 percent. However, it is generally believed that higher
doses are essential for preventing thromboxane-dependent
platelet activation. Studies by Wilson et al. demonstrated
that maximal plasma concentration of 12umol/L could be
achieved by a single oral 50mg dose of enteric-coated aspirin
[16]. This dose was found suﬃcient to cause signiﬁcant
inhibition of platelet function and daily ingestion of low-
dose aspirin demonstrated a cumulative eﬀect. In a separate
study, McLeod et al. used doses ranging from 50 to 3900mg
of aspirin and monitored platelet function, bleeding time,Thrombosis 3
and concluded that maximum dysfunction was obtained
with daily doses of about 100mg and no further changes
wereobservedinthesestudieswithhigherdoses[17].Several
workers have demonstrated the eﬃcacy of low-dose oral
aspirin in preventing platelet thromboxane production [2–
4, 17, 43]. Indeed one of these studies has demonstrated
beneﬁcial eﬀect of a dermal aspirin preparation on selective
inhibition of platelet prostaglandin synthase, sparing the
prostacyclin biosynthesis [31]. It is very well established that
100mg of aspirin per day is suﬃcient to signiﬁcantly reduce
the platelet thromboxane production [2–4, 19, 20, 33–35].
Furthermore, studies by McLeod et al. have shown that
dosages higher than 100mg per day do not produce any
greater inhibition of platelet function or enhance bleeding
times [17]. Therefore, it is reasonable to conclude that 80–
160mgs aspirin per day should be the choice for an ideal
preventive protocol [33]. However, there is considerable
room for improvement to maximize the beneﬁts by better
understanding the pharmacology of aspirin and platelet
physiology [2–4]. Itis possible to customize the aspirin treat-
mentbasedontheindividualpatientneeds.Onecanmonitor
the platelet prostaglandin synthase activity following aspirin
ingestion and recommend a dose that is appropriate [28–
34]. It is possible to monitor the platelet response to agonists
such as ADP or arachidonate and determine the degree of
inhibition by aspirinlike compounds [17]. In order to get
maximum inhibition of platelet COX1 enzymes, continuous
release aspirin formulations can be developed and tested
against currently available aspirin formulations. Platelets
are produced and released constantly to the circulation.
Therefore, a time-release aspirin, which would make avail-
able small amounts of aspirin into the circulation, may
be eﬀective. For instance, a 100mg formulation capable of
releasing 10mg acetyl salicylic acid per hour may be better
than a preparation which releases all of its active principle
in a short span of time. Using the strategy of slowing down
the release of active principle, newer formulations could be
used eﬀectively to provide needed amounts of the drug into
circulating blood at regular intervals. These novel formu-
lations may also provide selectivity of aspirin action by
preventing platelet thromboxane production and sparing the
endothelial prostacyclin synthesis. McLeod et al. studied the
eﬀect of various doses of aspirin (50, 100, 325, and 1000mg)
on platelet and vascular tissues [36]. They did not observe
inhibition of urinary 6-keto-PGF1 alpha production at low-
doses of 50 and 100mg. They attributed these ﬁndings to
the diﬀerential and selective inhibition of platelet function
and the sparring eﬀect of vascular COX1 enzymes. Sullivan
and associates studied the eﬀect of two diﬀerent doses of
aspirin on platelet function and TXA2 production [38].
Platelet function in healthy volunteers was inhibited by
both the doses (75 and 300mg). Low-dose failed to inhibit
completely TXB2 production 24 hours later, whereas 300mg
aspirin did. Even alternate day regimen of these doses
prevented platelet function and signiﬁcantly inhibited the
urinary levels of the 11-keto-TXB2. In a separate study, in
healthy volunteers, formation of thrombin (Fibrinopeptide
A; FPA), alpha granule release (beta-thromboglobulin; beta
TG), and thromboxane (TXB2) were monitored in vivo, in
blood emerging from a template bleeding incision [39]. At
the site of plug formation signiﬁcant platelet activation and
thrombin generation was observed as indicated by 110-fold,
50-fold, and 30-fold increase in FPA, beta TG, and TXB2,
within the ﬁrst minute. A low-dose regimen (0.42m/kg/day
for 7 days) caused greater than 90% inhibition of TXB2
formation in both bleeding time and clotted blood in these
studies, suggesting critical role of platelet activation at the
site of haemostatic plug formation. In a study to evaluate the
eﬀect of low-dose aspirin (0.5 and 15mg/kg/day) on platelet
and renal prostanoids, Wilson et al. monitored serum TXB2
and urinary 6-keto PGF1 alpha [40]. Serum TXB2 level was
reduced to 3% of control by low-dose and to 0.1% by the
higher dose. Urinary TXB2 was reduced only to 68% by
low-dose aspirin and to 51% by high dose. Urinary 6-keto-
PGF1 alpha was not reduced by either dose. Based on their
observation, they concluded that low-dose aspirin could
signiﬁcantly aﬀect platelet PG production without aﬀecting
stimulated release of PGI2 production.
5.ClinicalStudieson the Use of Aspirin
The two major clinical trials on aspirin concluded that inges-
tion of 160mg per day or 325mg alternative day provided
signiﬁcant beneﬁt in preventing fatal events associated with
CAD [19, 20]. Whereas, a 10-year trial involving nearly
40,000 women aged 45 and older with no evidence of
cardiovascular disease found that a regular alternate day
low-dose (100mg) aspirin was eﬀective in reducing the
incidence of stroke, but it did not have any eﬀect on the
incidence of heart attacks [41]. They concluded that the
reasonsforanysex-baseddiﬀerencesin the eﬃcacyofaspirin
for primary prevention are unclear. According to Minnesota
Heart Survey, about 6% of healthy women under age 65 and
30% of those over 65 take low-dose aspirin to prevent acute
vascular events [42]. Data from this primary prevention
study does not apply to women who already have had a heart
attack or heart surgery or diagnosed with coronary artery
disease. For such women, as found in men, regular daily
low-dose (80–160mg) of aspirin clearly reduces the risk of
developing acute coronary events.
Several earlier studies evaluated the eﬀect of low-dose
aspirin on normal healthy volunteers as well as patients with
various vascular diseases [38–41]. However, earlier studies
did not report prevalence of any aspirin resistance. Zucker et
al. evaluated the eﬀect of low-dose aspirin (0.45mg/kg/day)
and a high dose (900mg/day) in type 11 hyperlipoproteine-
mic subjects [43]. They found that low-dose aspirin eﬀec-
tively inhibited platelet function in these patients. Increased
platelet thromboxane production has been described in
several disorders including type 2 diabetes and type 11a
hypercholesterolemia. This increased production of TXB2
in hypercholesterolemic patients is attributed to abnormal
cholesterol levels in these patients. It has been shown that
even a low-dose of aspirin (50mg/7 days) signiﬁcantly
reduces 11-dehydro-TXB2, in these patients [44]. The eﬀect
of low-dose aspirin has been evaluated in patients with
diabetes, coronary heart disease, myocardial infarction (MI),4 Thrombosis
cerebrovascular disease, peripheral artery disease, and a
variety of surgical procedures [38–41]. DiMinno et al. stud-
ied the eﬀect of single doses of 100 and 1000mg aspirin for
1 month in normal volunteers and patients with diabetic
angiopathy [45]. They found a dose schedule of aspirin,
which may suﬃce in normal volunteers was not eﬀective in
patients with diabetic angiopathy. Contrary to this observa-
tion,Terresetal.foundalow-doseofaspirin(100mg)caused
signiﬁcant inhibition of platelet function in both healthy
subjects and patients with coronary heart disease [46].
Similarly, a low-dose (0.45mg/kg/day) was found adequate
for selective inhibition of TXA2-related platelet function, in
patients recovering from MI [47]. Looks like the results on
the eﬀect of low-dose aspirin vary considerably, depending
upon the type and stage of disease, dose of aspirin, and
severity of procedure. In a study evaluating the eﬀect of
low-dose aspirin (100mg) on hematological activity of left
ventricular (LV) thrombus in anterior wall acute MI (AMI),
Kupper et al. found that low dose had no eﬀect on the
incidence of hematologic activity and embolic potential of
LV thrombosis in anterior wall AMI [48]. On the other
hand, a low-dose aspirin (40mg/day) taken daily was found
to be as eﬀective as higher doses in preventing platelet
functional responses in patients who had recent cerebral
ischemia [49]. Uchiyama et al. evaluated the eﬀect of low-
dose aspirin, ticlopidine, and a combination of both these
drugs in patients with cerebral ischemia [50]. Aspirin alone
markedly inhibited platelet aggregation induced by AA,
partially inhibited aggregation induced by ADP and did not
inhibitaggregationbyplateletactivatingfactor.Combination
of these drugs inhibited aggregation by all agonists. Rao et al.
demonstrated,inhealthyvolunteers,thatlowdosesofaspirin
(40–80mg) had no inhibitory eﬀect on the response of
platelets to ADP, epinephrine, and thrombin, but eﬀectively
inhibited the platelet response to threshold concentrations
of AA [2, 3]. Epinephrine at concentrations too low to
cause aggregation restored the sensitivity of aspirin-treated
p l a t e l e t st oA A[ 51–54]. This phenomenon, in which weak
agonists restore the sensitivity of drug-induced refractory
platelets to the action of other agonists, was described from
our laboratory as “mechanism of membrane modulation”
[51–57].
6.AspirinResistance
Studies from our laboratory for the ﬁrst time demonstrated
that one could induce drug-mediated resistance in platelets
to the action of aspirin [58]. In this study, the subjects were
given a short acting inhibitor of COX1, Ibuprofen. This
was followed by administration of a full strength (325mg)
aspirin. Ibuprofen-mediated inhibition of COX1 enzyme
lasts for a short time, whereas aspirin-induced inhibition
is irreversible. Ibuprofen-treated platelets recovered their
sensitivity to the action of AA by 24hrs. Whereas aspirin-
treated platelets failed to respond to the action of AA even
after 24hrs. In those subjects who had ingested aspirin after
taking Ibuprofen ﬁrst, aspirin failed to inhibit irreversibly
the COX1, suggesting that Ibuprofen molecules eﬀectively
prevented the acetylation of COX1enzyme by aspirin.
One of the earliest works describing “nonresponders” and
“responders” evaluated the eﬀect of low-dose aspirin and
a thromboxane synthetase inhibitor dazoxiben (UK3724B)
in healthy subjects [59]. These studies demonstrated that
low-dose aspirin and ingestion of two dazoxiben tablets
prevented the release of granules from platelets in response
to AA in some individuals (responders) and not in others
(nonresponders). These subtle diﬀerences in response of
platelets to various drugs as well as diﬀerences in response
to various agonists may be critical when considering the out-
come of acute vascular events. For instance, collagen seems
to exert its eﬀect by multiple mechanisms. In a study,
using aspirin, monoclonal antibodies to 11b-111a receptor
and ﬁbrinogen, it was demonstrated that there exist at
least three mechanisms by which collagen activates platelets:
(1) GP11b-111a-associated activation, (2) prostaglandin-
dependent pathway, and (3) alternate pathway responsible
for 20–30% platelet aggregation [60].
Several recent studies have demonstrated drug resistance
in patients with a variety of vascular diseases [61–95]. This
subject currently is a very hot topic and has made national
headlines. Andrew Pollack published an article in July of
2004 in New York Times, on this subject titled, “For Some,
Aspirin May Not Help Hearts” [62]. According to this article,
5–40% of aspirin users are “nonresponders” or “resistant”
to the drug. In the same article, he cites the opinion of
Dr. Daniel I. Simon, the associate director of interventional
cardiologyatBrighamandWomen’sHospital,Boston,which
reads as follows: “They are taking it for stroke and heart
attack prevention and it’s not going to work.” He also reports
the opinion of Dr. Michael J. Domanski; head of clinical
trials unit at the NIH; in his opinion, the nonresponders
may represent a huge number of patients. According to
Dr. Deepak L. Bhatt, director of interventional cardiology
Cleveland Clinic, aspirin resistance is associated with worst
outcome. Professor Eric Topol, Chairman, Cardiovascular
Medicine Cleveland Clinic, USA states, “Aspirin resistance
carries high risk, with over 20 million Americans taking
aspirintopreventheartattacksorstrokes,itisimportantthat
further work to be done to conﬁrm our ﬁndings and develop
arapiddetectionmethod.Healsoassuresthatforindividuals
with aspirin resistance, there are excellent alternatives.”
These observances from health care providers and re-
searchers raise number of issues. Do we know enough
about aspirin resistance? What is the prevalence of aspirin
resistance in healthy population? What causes this resistance
to develop in patient populations? Are there speciﬁc, rapid,
cost-eﬀective tests available? What alternative long-term
treatments are available, if patients are resistant to common
antiplatelet drugs such as aspirin and Clopidogrel? Should
the doses of these drugs used for therapy be increased?
Shouldweusedualantiplatelettherapyorusemorethantwo
antiplatelet drugs? Should we drop the use of these drugs in
nonresponders? We need to ﬁnd answers to these and other
emerging questions soon. In the next few paragraphs a brief
overview of what is known about the prevalence of aspirin
resistance,clinicalﬁndings,andmethodologiesavailable,will
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The ﬁrst and foremost need at this time is to standardize
adeﬁnitionofaspirinresistance.Themechanismofactionof
aspirin is very well documented [5–13]. The drug acetylates
the platelet COX1 enzyme and irreversibly inhibits its ability
t oc o n v e r tA At oP Ge n d o p e r o x i d e s[ 11, 12]. In the absence
of COX1 enzyme activity, platelets do not respond to AA
stimulation with aggregation. Weak agonists such as ADP,
Epinephrine depend on the formation of PG endoperoxides
to initiate secondary wave of aggregation and promote
release of platelet granule contents [2, 3].Therefore, weak
agonists fail to induce platelet aggregation and release gran-
ules from aspirin-treated platelets. Failure of AA, ADP, and
Epinephrine to cause aggregation of platelets more or less
establishes drug-induced platelet dysfunction. If platelets
obtained from individuals who have ingested a full strength
aspirin, respond with aggregation to the action AA, ADP
and EPI, and release their granule contents, then one can
safely conclude that these platelets are resistant to aspirin
action. Further proof for aspirin resistance of platelets can
be provided by studying AA metabolism by such platelets,
monitoring serum TXB2 levels, or urinary levels of TXB2
or its metabolite, 11-dehydro-TXB2. Methods are available
to monitor all these parameters. According to Cattaneo,
“aspirin resistant” should be considered as description for
those individuals whom aspirin fails to inhibit thromboxane
A2 production, irrespective of the results of unspeciﬁc tests
of platelet function [93].
7. Prevalenceof Aspirin Resistance
Aspirin resistance has been poorly deﬁned, variety of non-
speciﬁcmethodshavebeenemployedtomonitorthe“aspirin
resistance” and conﬂicting reports have been published on
the rates of prevalence and outcome of continuing this
therapeutic modality [62–79]. Aspirin resistance has been
reported in patients with cardiovascular, cerebrovascular
and peripheral vascular disease [75–93]. Because of the
diﬀerences in methodologies used to monitor this phe-
nomenon and lack of a speciﬁc assay to determine the
true aspirin resistance, there is considerable confusion and
the true signiﬁcance of this observation remains obscure
[62–64]. It also raises the question, as to how we missed
this phenomenon of drug resistance all these years? Large
numbers of clinical trials have demonstrated the beneﬁcial
eﬀects of aspirin therapy irrespective of the disease state
[33]. Is it possible that these earlier trials missed aspirin
nonresponders? On the other hand, it is quite possible that
only responders to the action of aspirin got the beneﬁt of this
therapy.
Studies in our laboratory over three decades have failed
to show any aspirin resistance in normal healthy subjects.
The only subject whose platelets failed to aggregate in re-
sponse to AA stimulation was found to be deﬁcient in
platelet COX1enzyme activity [53]. Platelets obtained from
this subject responded with aggregation when stirred with
epinephrine and arachidonate, suggesting that PG endoper-
oxides and TAX2 are not essential to cause irreversible aggre-
gation of platelets. There is no much data on the prevalence
of aspirin resistance in general healthy subjects. In patients
with various vascular diseases, the rate of nonresponders
reported varies between less than 2% to over 60%. Since the
methods used to monitor aspirin resistance in these reports
are not speciﬁc, the prevalence rate published is debatable
[62–79].
Hurlen et al. used the method of Wu and Hoak to
determine the platelet aggregation ratio as a marker for
assessing platelet function and evaluated the eﬀect of aspirin
(160mg/day) in 143 patients who had survived myocardial
infarction [67, 68]. Based on their deﬁnition of nonre-
sponders to the action of aspirin, they could only identify
two subjects as primary nonresponders. Gum et al. from
Cleveland Clinic studied 326 stable cardiovascular subjects
on aspirin (325mg/day) and tested aspirin sensitivity by
platelet response to aggregating agents such as ADP and
AA. They found 5.5% as nonresponders to aspirin and 24%
as semiresponders [69]. Gum and associates used the PFA-
100, a method that measures platelet function, to determine
aspirin resistance in their patient population [70]. Based on
the results of their studies with this methodology, they found
9.5% to be nonresponders to aspirin action.
Some studies have reported as high as 30–40% nonre-
sponders of stroke or vascular disease patients and predicted
>80% increased risk for a repeat event during a 2-year
follow-upperiod[70–74].Eikelboometal.analyzedbaseline
urinary levels of TXB2 metabolites 11-dehydrothromboxane
B2 in 5529 patients enrolled in the Heart Outcomes
Prevention Evaluation (HOPE) study [89, 90]. Of these
subjects 488 were on aspirin regimen. On the basis of their
ﬁndings they concluded that in aspirin-treated patients,
increased levels of urinary metabolite of TXB2 predict future
risk of myocardial infarction or cardiovascular death. The
patients with the highest levels of urinary TXB2 metabolite
had 3–5-fold higher risk of cardiovascular death compared
to those in the lowest quartile. Another study reporting
clinical outcomes of aspirin resistance is from Austria
[71, 73, 76]. In this study patients undergoing arterial
angioplasty were on 100mg aspirin per day. Platelet function
was assessed by whole blood aggregometry. This study
demonstrated that reocculsion at the sites of angioplasty
occurred only in men for whom platelet dysfunction was
e v i d e n tb ya g g r e g o m e t r y[ 78]. Zimmerman et al. identiﬁed
aspirin nonresponders as those who had >90% inhibition
of TXB2 formation in presence of 100umol/L aspirin and
1mmol/L arachidonate [78]. In patients who had under-
gone coronary bypass surgery (CABG), AA and Collagen
stimulated formation of TXB2 was same before and after
CABG, indicating that oral aspirin did not signiﬁcantly
inhibit platelet COX1. However, the in vitro studies with
100umol/L aspirin on blood obtained from these subjects
showed decreased TXB2 (>10%) in most samples studied.
They concluded that platelet COX1 inhibition by aspirin is
compromised for several days after CABG, probably due to
an impaired interaction between aspirin and platelet COX1.
This observation indicates how complex the issues are when
evaluating the eﬀect of antiplatelet drugs during and after
interventional procedures. Sane et al. evaluated the eﬀect
of aspirin (325mg/day/month) in patients suﬀering from
congestive heart failure [79]. These researchers used whole6 Thrombosis
blood aggregometry (Chronolog Corp, PA, USA), Platelet
receptor expression by ﬂow cytometry and PFA-100. Patients
were considered nonresponders when 4 of the 5 parameters
assayed were observed. Using this complex rating, persistent
platelet activation was observed in 50 of the 88 patients
(56.8%). These observations remind us of the inadequacy of
the existing methods to detect what truly represents “aspirin
resistance.”
8. Aspirin Therapy: Expectations
andLimitations
Data from over ﬁve hundred clinical studies have demon-
strated that at any given risk for the development of acute
vascular events, irrespective of the disease state, aspirin at
low-to-medium concentration is as eﬀective as any other
antiplatelet drug in reducing the risks [4]. In view of these
observations, patients as well as physicians who are treating
them, expect maximum protection from such an antiplatelet
therapy. However, recent studies have demonstrated that
close to 30% of the patients on aspirin prophylaxis may be at
risk for developing acute vascular events. These revelations
have caused considerable confusion in the minds of medical
community as well as patients, who are taking antiplatelet
drugs. It is important to realize ﬁrst of all that aspirin is
short lived in the circulation and as such only the platelets
(COX enzymes), which get exposed to aspirin in the blood
during its short period of activity, are permanently inhibited.
In addition, bone marrow produces platelets continuously
and delivers them into circulating blood; therefore, those
platelets that are released after aspirin is hydrolyzed will not
haveanyinhibitoryeﬀectofaspirinontheirCOX-1enzymes.
Studies from our laboratory also have demonstrated that
platelets lacking COX-1 enzymes as well as those in which
theactivityhasbeeninhibitedbyaspirinrespondinanormal
fashion and aggregate to the response of arachidonate in the
presence of epinephrine, although they do not produce any
proaggregatory PG metabolites [35, 51–54, 59]. Studies from
our laboratory as well as that of others have demonstrated
that patients on aspirin prophylaxis may still produce
large amounts of urinary metabolites of pro-aggregatory
thromboxane in spite of the fact that COX-1 enzymes of
platelets are inhibited in these individuals.
In spite of the high expectations of clinicians as well
as patients who are on aspirin prophylaxis, it is reasonable
to assume that there is a fair percentage of individuals
on antiplatelet drugs who are at risk for developing acute
vascular events [90–95]. Therefore, clinicians should assess
the risk for these patients by monitoring urinary metabolites
of thromboxane, so that if the levels are signiﬁcantly above
normal, then patients have to be provided additional or
alternate antiplatelet therapy [95]. Some of the suggested
therapies include using instead of single daily dose of
aspirin, multiple doses (Eg: 80mg twice or thrice a day
instead of single 80 or 160mg). Those found with excess
of urinary thromboxane levels may be put on thromboxane
antagonists.AlternatetherapiessuchuseofTriﬂusal(ﬂuoride
derivative of aspirin) or omega three acid capsules can also
be tested [96]. If tests to determine urinary metabolites
of prostaglandins are not available, then a simple platelet
function test with arachidonate as agonists would serve
the purpose. Newer instruments are being developed which
measure coagulation proﬁle on nonanticoagulated blood
PlaCor Platelet reaction testing (PlaCor Inc, Minneapolis,
MN) or Aggredyne Platelet function Monitor (Aggredyne,
Houston, TX) [97]. Major take-home message, however,
when considering the beneﬁts of antiplatelet therapy is that
if the platelet functions are not inhibited by the speciﬁc
antiplatelet drug they are taking, then the patients are “at
risk” for acute vascular events.
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